Clinical Trial Update: Study to Evaluate the Immune Response After a Booster Dose of a Quadrivalent Meningococcal (MenACYW) Conjugate Vaccine When Administered Alone or Concomitantly With a Licensed Meningococcal Serogroup B Vaccine, in Participants Who Received Primary Quadrivalent Meningococcal Conjugate Vaccine (MCV4) [Phase 3]

View source ↗

Summary

Phase 3 study assessing the immune response to a booster dose of MenACYW Conjugate Vaccine given alone or with a licensed meningococcal serogroup B vaccine in p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• Licensed Meningococcal Serogroup B Vaccine
• MenACYW Conjugate Vaccine (MenACWY conjugate vaccine)

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningococcal Immunisation (Healthy Volunteers) | Phase 3 | Status: COMPLETED | Results posted: 2021-08-30